Receptor Determinants of Hallucinogen Actions

Sealfon, Stuart C.

Abstract

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Institute on Drug Abuse (NIDA)
• Type: Research Project (R01)
• Project #: 5R01DA009088-03
• Application #: 2122065
• Study Section: Drug Abuse Biomedical Research Review Committee (DABR)
• Project Start: 1994-09-01
• Project End: 1999-07-31
• Budget Start: 1996-08-01
• Budget End: 1997-07-31
• Support Year: 3
• Fiscal Year: 1996

Institution

• Name: Mount Sinai School of Medicine
• Department: Other Basic Sciences
• Type: Schools of Medicine
• City: New York
• State: NY
• Country: United States
• Zip Code: 10029

Publications

Klein, C; Gurvich, N; Sena-Esteves, M et al. (2000) Evaluation of the role of the D2 dopamine receptor in myoclonus dystonia. Ann Neurol 47:369-73

Shashidharan, P; Chalmers-Redman, R M; Carlile, G W et al. (1999) Nuclear translocation of GAPDH-GFP fusion protein during apoptosis. Neuroreport 10:1149-53

Almaula, N; Ebersole, B J; Ballesteros, J A et al. (1996) Contribution of a helix 5 locus to selectivity of hallucinogenic and nonhallucinogenic ligands for the human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors: direct and indirect effects on ligand affinity mediated by the same locus. Mol Pharmacol 50:34-42

Almaula, N; Ebersole, B J; Zhang, D et al. (1996) Mapping the binding site pocket of the serotonin 5-Hydroxytryptamine2A receptor. Ser3.36(159) provides a second interaction site for the protonated amine of serotonin but not of lysergic acid diethylamide or bufotenin. J Biol Chem 271:14672-5

Sealfon, S C; Chi, L; Ebersole, B J et al. (1995) Related contribution of specific helix 2 and 7 residues to conformational activation of the serotonin 5-HT2A receptor. J Biol Chem 270:16683-8